News | June 22, 2009

PET Core Laboratory Plays Critical Role in Insuring Reliable Research Results

June 23, 2009 - The positron emission tomography (PET) core laboratory of the American College of Radiology Clinical Research Center serves a critical role ensuring images and image data from PET scanners used in multicenter clinical trial research meet acceptable standards according to a paper published online June 12 in the Journal of Nuclear Medicine.

This finding was based on a review of the PET scanner qualification program of the American College of Radiology Imaging Network (ACRIN) and reported by the PET core laboratory team of physicists, nuclear medicine physicians and technologists supporting the program.

“Information obtained from PET imaging has increasingly demonstrated its promising role as a non-invasive biomarker for assessing disease status. The goal of the PET qualification program is to insure we are obtaining reliable quantitative and qualitative data across all of the centers participating in PET clinical research,” states lead author Joshua Scheuermann, MS, a clinical physicist at the University of Pennsylvania.

In the past three years, ACRIN has activated a number of clinical trials with PET imaging endpoints and several more are poised to activate in the near future. The PET qualification program requires sites intending to participate in these multi-center trials to demonstrate the scanner to be used in the research protocol meets acceptable calibration standards for obtaining the standardized uptake value (SUV) and production of high quality images. “In the past several years, ACRIN has significantly expanded its PET research, and we are excited about future research projects that will evaluate novel PET radiopharmaceuticals,” says Anthony Levering, RT(R)(CT)(MR),CIIP, an assistant director of the core laboratory. “The PET qualification program provides a high level of confidence regarding the consistent handling of data.”

The authors reviewed data on the qualification of 101 PET scanners for which complete qualification data were available. They reported that, in total, of the 101 scanners to apply for PET qualification from June 2005 through June 2008, 36 sites passed the qualification review with no intervention, 57 sites passed with some type of intervention and eight sites failed and opted not to continue with the qualification process.

“The PET scanner qualification process is rigorous and requires considerable site commitment. Having qualified nearly 170 PET scanners for ACRIN research participation, it was important to evaluate the program to ensure it was making a significant difference in the quality of data collected. These results highlight the importance of a central review of a site’s data and images before data accrued on a PET scanner are used in a multi-center trial,” comments PET core laboratory medical director Barry Siegel, M.D., from Mallinckrodt Institute of Radiology at Washington University School of Medicine.

The PET core laboratory is a key component of the Diagnostic Imaging and Radiation Oncology Core Laboratory of the ACR’s Clinical Research Center located in Philadelphia. The laboratory services the center’s four research entities: ACRIN, the Radiation Therapy Oncology Group, Quality Research in Radiation Oncology, and the ACR Image Metrix.

For more information:,,, and

Related Content

ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....